Skip to main content
SpringerLink
Log in
Book cover

Inflammatory Breast Cancer: An Update pp 67–73Cite as

Surgical Therapy for Inflammatory Breast Cancer

  • Chapter
  • First Online:

  • 808 Accesses

Abstract

Surgical therapy for inflammatory breast cancer (IBC), the most aggressive and fatal form of breast cancer, continues to challenge surgeons. Surgical therapy should only be undertaken in patients with IBC who respond to neoadjuvant chemotherapy (NAC). The recommended definitive surgical treatment for IBC is modified radical mastectomy. Currently, breast conserving therapy, skin-sparing mastectomy, nipple-sparing mastectomy, sentinel lymph node biopsy, and immediate breast reconstruction are contraindicated for patients with IBC. Multimodality treatment, including surgery, is crucial for achieving optimal outcomes.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Lee BJ, Tannenbaum NE (1924) Inflammatory carcinoma of the breast. Clin Radiol 39:580–595

    Google Scholar 

  2. Haagensen CD, Stout AP (1951) Carcinoma of the breast. III. Results of treatment. Ann Surg 134:151–170

    Article  PubMed  CAS  Google Scholar 

  3. Barber KW Jr, Dockerty MB, Clagett OT (1961) Inflammatory carcinoma of the breast. Surg Gynecol Obstet 112:406–410

    PubMed  Google Scholar 

  4. Bozzetti F, Saccozzi R, De Lena M, Salvadori B (1981) Inflammatory cancer of the breast: analysis of 114 cases. J Surg Oncol 18:355–361

    Article  PubMed  CAS  Google Scholar 

  5. Barker JL, Nelson AJ, Montague ED (1976) Inflammatory carcinoma of the breast. Radiology 121:173–176

    PubMed  CAS  Google Scholar 

  6. Zucali R, Uslenghi C, Kenda R, Bonadonna G (1976) Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy. Cancer 37:1422–1431

    Article  PubMed  CAS  Google Scholar 

  7. Thoms WW Jr, McNeese MD, Fletcher GH, Buzdar AU, Singletary SE, Oswald MJ (1989) Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys 17:739–745

    Article  PubMed  Google Scholar 

  8. Buzdar AU, Montague ED, Barker JL, Hortobagyi GN, Blumenschein GR (1981) Management of inflammatory carcinoma of breast with combined modality approach – an update. Cancer 47:2537–2542

    Article  PubMed  CAS  Google Scholar 

  9. Knight CD Jr, Martin JK Jr, Welch JS, Ingle JN, Gaffey TA, Martinez A (1986) Surgical considerations after chemotherapy and radiation therapy for inflammatory breast cancer. Surgery 99:385–391

    PubMed  Google Scholar 

  10. Zylberberg B, Salat-Baroux J, Ravina JH, Dormont D, Amiel JP, Diebold P, Izrael V (1982) Initial chemoimmunotherapy in inflammatory carcinoma of the breast. Cancer 49:1537–1543

    Article  PubMed  CAS  Google Scholar 

  11. Cristofanilli M, Buzdar AU, Sneige N, Smith T, Wasaff B, Ibrahim N, Booser D, Rivera E, Murray JL, Valero V, Ueno N, Singletary ES, Hunt K, Strom E, McNeese M, Stelling C, Hortobagyi GN (2001) Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer 92:1775–1782

    Article  PubMed  CAS  Google Scholar 

  12. Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, Kau SW, Frye DK, Hortobagyi GN (2004) Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M.D. Anderson Cancer Center experience. Clin Breast Cancer 4:415–419

    Article  PubMed  CAS  Google Scholar 

  13. Dawood S, Gonzalez-Angulo AM, Peintinger F, Broglio K, Symmans WF, Kau SW, Islam R, Hortobagyi GN, Buzdar AU (2007) Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M.D. Anderson experience. Cancer 110:1195–1200

    Article  PubMed  CAS  Google Scholar 

  14. Hurley J, Doliny P, Reis I, Silva O, Gomez-Fernandez C, Velez P, Pauletti G, Powell JE, Pegram MD, Slamon DJ (2006) Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 24:1831–1838

    Article  PubMed  CAS  Google Scholar 

  15. Van Pelt AE, Mohsin S, Elledge RM, Hilsenbeck SG, Gutierrez MC, Lucci A Jr, Kalidas M, Granchi T, Scott BG, Allred DC, Chang JC (2003) Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer 4:348–353

    Article  PubMed  Google Scholar 

  16. Limentani SA, Brufsky AM, Erban JK, Jahanzeb M, Lewis D (2003) Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2 –overexpressing locally advanced breast cancer. J Clin Oncol 25:1232–1238

    Article  Google Scholar 

  17. Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP (2003) Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast ­cancer: a pilot study. J Clin Oncol 21:46–53

    Article  PubMed  CAS  Google Scholar 

  18. Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M (2011) International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 22:515–523

    Article  PubMed  CAS  Google Scholar 

  19. Ueno NT, Buzdar AU, Singletary SE, Ames FC, McNeese MD, Holmes FA, Theriault RL, Strom EA, Wasaff BJ, Asmar L, Frye D, Hortobagyi GN (1997) Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M.D. Anderson Cancer Center. Cancer Chemother Pharmacol 40:321–329

    Article  PubMed  CAS  Google Scholar 

  20. Chevallier B, Roche H, Oliver JP, Chollet P, Hurteloup P (1993) Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 16:223–228

    Article  PubMed  CAS  Google Scholar 

  21. Kell MR, Morrow M (2005–2006) Surgical aspects of inflammatory breast cancer. Breast Dis 22:67–73

    Google Scholar 

  22. Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, Colleoni M, Denkert C, Eiermann W, Jackesz R, Makris A, Miller W, Pierga JY, Semiglazov V, Schneeweiss A, Souchon R, Stearns V, Untch M, Loibl S (2007) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 18:1927–1934

    Article  PubMed  CAS  Google Scholar 

  23. Arthur DW, Schmidt-Ullrich RK, Friedman RB, Wazer DE, Kachnic LA, Amir C, Bear HD, Hackney MH, Smith TJ, Lawrence W Jr (1999) Accelerated superfractionated radiotherapy for inflammatory breast carcinoma: complete response predicts outcome and allows for breast conservation. Int J Radiat Oncol Biol Phys 44:289–296

    Article  PubMed  CAS  Google Scholar 

  24. De Boer RH, Allum WH, Ebbs SR, Gui GP, Johnston SR, Sacks NP, Walsh G, Ashley S, Smith IE (2000) Multimodality therapy in inflammatory breast cancer: is there a place for surgery? Ann Oncol 11:1147–1153

    Article  PubMed  Google Scholar 

  25. Swain SM, Sorace RA, Bagley CS, Danforth DN Jr, Bader J, Wesley MN, Steinberg SM, Lippman ME (1987) Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 47:3889–3894

    PubMed  CAS  Google Scholar 

  26. Harris EE, Schultz D, Bertsch H, Fox K, Glick J, Solin LJ (2003) Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys 55:1200–1208

    Article  PubMed  Google Scholar 

  27. Hortobagyi G, Singletary S, Strom E (2000) Treatment of locally advanced and inflammatory breast cancer. Lippincott, Williams & Wilkins, Philadelphia

    Google Scholar 

  28. Vlastos G, Fornage BD, Mirza NQ, Bedi D, Lenert JT, Winchester DJ, Tolley SM, Ames FC, Ross MI, Feig BW, Hunt KK, Buzdar AU, Singletary SE (2000) The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy. Am J Surg 179:446–452

    Article  PubMed  CAS  Google Scholar 

  29. Woodward WA, Cristofanilli M (2009) Inflammatory breast cancer. Semin Radiat Oncol 19:256–265

    Article  PubMed  Google Scholar 

  30. Curcio LD, Rupp E, Williams WL, Chu DZ, Clarke K, Odom-Maryon T, Ellenhorn JD, Somlo G, Wagman LD (1999) Beyond palliative mastectomy in inflammatory breast cancer – a reassessment of margin status. Ann Surg Oncol 6:249–254

    Article  PubMed  CAS  Google Scholar 

  31. Mamounas EP, Brown A, Anderson S, Smith R, Julian T, Miller B, Bear HD, Caldwell CB, Walker AP, Mikkelson WM, Stauffer JS, Robidoux A, Theoret H, Soran A, Fisher B, Wickerham DL, Wolmark N (2006) Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 23:2694–2702

    Article  Google Scholar 

  32. Classe JM, Bordes V, Campion L, Mignotte H, Dravet F, Leveque J, Sagan C, Dupre PF, Body G, Giard S (2009) Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of ganglion sentinelle et chimiotherapie neoadjuvante, a French prospective multicentric study. J Clin Oncol 27:726–732

    Article  PubMed  Google Scholar 

  33. Stearns V, Ewing CA, Slack R, Penannen MF, Hayes DF, Tsangaris TN (2002) Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 9:235–242

    Article  PubMed  Google Scholar 

  34. Chin PL, Andersen JS, Somlo G, Chu DZ, Schwarz RE, Ellenhorn JD (2000) Esthetic reconstruction after mastectomy for inflammatory breast cancer: is it worthwhile? J Am Coll Surg 190:304–309

    Article  PubMed  CAS  Google Scholar 

  35. Schechter NR, Strom EA, Perkins GH, Arzu I, McNeese MD, Langstein HN, Kronowitz SJ, Meric-Bernstam F, Babiera G, Hunt KK, Hortobagyi GN, Buchholz TA (2005) Immediate breast reconstruction can impact postmastectomy irradiation. Am J Clin Oncol 28:485–494

    Article  PubMed  Google Scholar 

  36. Motwani SB, Strom EA, Schechter NR, Butler CE, Lee GK, Langstein HN, Kronowitz SJ, Meric-Bernstam F, Ibrahim NK, Buchholz TA (2006) The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys 66:76–82

    Article  PubMed  Google Scholar 

  37. Behranwala KA, Dua RS, Ross GM, Ward A, A’hern R, Gui GP (2006) The influence of radiotherapy on capsule formation and aesthetic outcome after immediate breast reconstruction using biodimensional anatomical expander implants. J Plast Reconstr Aesthet Surg 59:1043–1051

    Article  PubMed  CAS  Google Scholar 

  38. Tran NV, Chang DW, Gupta A, Kroll SS, Robb GL (2001) Comparison of immediate and delayed free TRAM flap breast reconstruction in patients receiving postmastectomy radiation therapy. Plast Reconstr Surg 108:78–82

    Article  PubMed  CAS  Google Scholar 

  39. Rogers NE, Allen RJ (2002) Radiation effects on breast reconstruction with the deep inferior epigastric perforator flap. Plast Reconstr Surg 109:1919–1924; discussion 1925–1926

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler st, Unit 1484, Houston, TX, 77030, USA

    Sarah M. Gainer & Anthony Lucci

  2. Breast Surgical Oncology, St Luke’s International Hospital, 9-1, Akashi-Cho, Chuo-ku, 104-8560, Japan

    Hideko Yamauchi

Authors
  1. Sarah M. Gainer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hideko Yamauchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anthony Lucci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideko Yamauchi .

Editor information

Editors and Affiliations

  1. MD Anderson Cancer Center, Dept. Breast Medical Oncology, University of Texas, Holcombe Blvd. 1515, Houston, 77030-4095, Texas, USA

    Naoto T. Ueno

  2. Fox Chase Cancer Center, Cottman Avenue; Room C315 333, Philadelphia, 19111, Pennsylvania, USA

    Massimo Cristofanilli

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Gainer, S.M., Yamauchi, H., Lucci, A. (2012). Surgical Therapy for Inflammatory Breast Cancer. In: Ueno, N., Cristofanilli, M. (eds) Inflammatory Breast Cancer: An Update. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-3907-9_7

Download citation

Publish with us

Policies and ethics

Search

Navigation